The FDA Just Fast-Tracked Your Peptide Habit
RFK Jr. and Joe Rogan wanted easier access to injectable peptides. A federal panel just gave it to them — over the loud objections of, well, everyone with an MD.
Two years ago, "peptides" was a word you half-remembered from a college biochem class and never thought about again. Now it's the thing your trainer, your dermatologist, and — inexplicably — the Secretary of Health and Human Services will not stop talking about. Last month, a federal advisory panel voted 8 to 6 (basically a coin flip with a lab coat on) to make it easier for compounding pharmacies to sell six previously restricted peptides, including BPC-157, the substance Joe Rogan's audience nicknamed the "Wolverine stack." The fallout is still rolling in this week, and it's worth understanding what actually happened before your group chat talks you into ordering something off a website with a padlock icon and zero spelling consistency.
What the Vote Actually Does (and Very Pointedly Doesn't)
Here's the part getting lost in the group-chat version of this story: the FDA's Pharmacy Compounding Advisory Committee didn't approve anything. What it voted on, narrowly, was whether to add BPC-157, TB-500, KPV, and a handful of other peptides to the 503A bulk list — the list that lets specialty compounding pharmacies legally mix and sell a substance without it going through the normal drug-approval gauntlet. FDA staff scientists, who reviewed the same handful of small human studies everyone else did, said plainly that the evidence "lacks" support for effectiveness. The committee voted for broader access anyway. That's not a regulatory rubber stamp — it's a "we'll allow the pharmacy to sell it, science TBD" shrug, which is a meaningfully different thing than the headlines suggest.
The Rogan-RFK Effect
None of this happened in a vacuum. Health Secretary Robert F. Kennedy Jr. has called himself a "big fan" of peptides, and Joe Rogan has spent a small eternity of podcast hours describing how BPC-157 and TB-500 — together, the aforementioned Wolverine stack — supposedly rebuild torn tissue on a timeline that would make an actual mutant jealous. When your health secretary and the most listened-to podcast host in the country are both personally invested in a supplement category, an advisory committee voting narrowly in its favor stops looking like neutral science and starts looking like policy catching up to vibes. Critics, including several physicians who sat on the panel, called the current peptide market exactly what it is: a "Wild West" of research chemicals, sourced from overseas labs and shipped in vials that were never meant to end up in a bathroom cabinet next to the retinol.
Longevity physician Peter Attia — not exactly a wellness skeptic by trade — has been one of the louder voices pumping the brakes, calling BPC-157 "great marketing, not great science" after three decades of claims with no standout human data to show for it. Which is the useful frame here: this isn't wellness bros versus humorless doctors. It's a genuinely split room, and the people in the room with the most to lose from being wrong are the ones now allowed to sell it to you.
What Doctors Keep Bringing Up (That TikTok Skips)
The specific worry isn't vague "big pharma doesn't want you to know" energy — it's oddly specific. Physicians flagged the theoretical risk of unvetted, growth-promoting peptides interacting with cancer-related cell signaling, plus more immediate concerns like injection-site infections and immune reactions, since most of what's being sold isn't manufactured to pharmaceutical-grade standards. None of that means BPC-157 is secretly dangerous for everyone who's tried it. It means the studies that would tell us either way largely don't exist yet, and "largely don't exist yet" is doing a lot of quiet, unglamorous work under all those glowing recovery testimonials.
If You're Still Curious, Start Here Instead
The good news, if you're peptide-curious but not eager to become a case study: the injectable version isn't the only door in. The skincare industry got to "peptides" years before the biohackers did, and it's a considerably lower-stakes place to dabble — even Gwyneth Paltrow's Goop has pivoted its peptide messaging toward "stacking" serums rather than syringes. If you want the topical version of this trend without the regulatory cliffhanger, the goop Youth-Boost Peptide Serum is the brand's own bet on the category, layering peptides with NAD+ for the anti-aging crowd. For something more clinical and considerably less expensive, The Ordinary's "Buffet" Multi-Peptide Serum has quietly been the internet's most-repurchased peptide product for years, no press cycle required. And if you want a dermatologist-adjacent option, Dr. Dennis Gross's Ferulic + Retinol Anti-Aging Boost Serum pairs peptides with retinol for the layering-obsessed. All three work on your face, not your fascia, which is precisely the point.
If the injectable side of this still appeals to you specifically because a podcast host with a very large following made it sound like a superpower, our running list of wellness trends worth a second thought is a good place to slow down before you do. And if you're the kind of person who reads regulatory news for the plot twists, we keep tabs on this exact category in our archive of celebrity wellness habits worth stealing (or skipping).
Peptides aren't going away — not with this much political and cultural momentum behind them, and not with a health secretary this personally enthusiastic. But "recently cleared for pharmacy compounding" and "clinically proven to work" are two very different sentences, and the gap between them is exactly where you don't want to be the one running the experiment. Read the label. Ask your actual doctor, not your favorite account's. And maybe start with the serum.
Frequently Asked Questions
Did the FDA actually approve BPC-157?
Not exactly, and this is the part worth repeating. The Pharmacy Compounding Advisory Committee’s 8–6 vote only recommends adding BPC-157 and five other peptides to the 503A bulk list, which would let compounding pharmacies legally mix and sell them. That’s different from full FDA drug approval — the agency’s own staff scientists said the evidence "lacks" support for effectiveness, and the committee voted for broader access anyway.
What is BPC-157, and why do people call it the “Wolverine stack”?
BPC-157 is a synthetic peptide originally studied for gut healing that’s gone viral off-label for tissue and joint recovery. Paired with TB-500, another peptide, it earned the "Wolverine stack" nickname from Joe Rogan’s audience for its supposed rapid-healing claims — claims that outpace the actual human data, according to physicians like Peter Attia.
Is it safe?
Nobody can say for certain yet. Physicians on the FDA panel flagged the theoretical risk of unregulated, growth-signaling peptides interacting with cancer-related cell pathways, plus more immediate concerns like injection-site infections and immune reactions — especially given how much of the current supply comes from unregulated overseas labs rather than pharmaceutical-grade manufacturing.
I’m curious but not ready to inject anything — where should I start?
Topically. Peptide skincare has years of category development behind it and a far lower risk profile than the injectable version — see our product picks above for where to start.